Advancing the Frontier of Fungal Live Biotherapeutics: From Ecological Niche to Clinical Solution
The landscape of modern medicine is undergoing a seismic shift, moving beyond traditional small molecules toward the sophisticated engineering of living systems. At the heart of this revolution lies the fungal kingdom, a diverse, resilient, and biochemically rich domain that offers unparalleled potential for human health. As a leading Contract Research Organization (CRO) specializing in preclinical development, Creative Biolabs recognizes that fungi are no longer just the "other" microbe; they are the next generation of therapeutic powerhouses. Our mission is to bridge the gap between basic mycological research and robust preclinical validation, ensuring that your fungal-based Live Biotherapeutic Products (LBPs) reach the clinic with safety, efficacy, and scientific rigor.
Overview: The Rise of Mycotherapy in Live Biotherapeutics
While the "microbiome" has long been synonymous with bacteria, the mycobiome, the fungal community within the human body, is increasingly recognized as a critical regulator of systemic health. Fungi possess unique structural and metabolic attributes that distinguish them from bacterial probiotics. Their large cell size, complex cell wall structures (comprising glucans and chitin), and ability to secrete a wide array of bioactive enzymes make them ideal candidates for treating complex multi-factorial diseases.
In the context of Live Biotherapeutics, fungi are being leveraged not just for their natural commensal properties, but as sophisticated "chassis" for synthetic biology. Unlike many bacteria, certain fungal strains are remarkably resistant to antibiotics, allowing them to be administered alongside standard treatments without losing viability. This makes them a strategic choice for treating secondary infections or maintaining gut homeostasis during intensive medical interventions.
Navigating the Fungal Landscape: Our Core Research Focus
To help you navigate the specific therapeutic potential of different fungal species, we have categorized our primary preclinical research and development efforts into six key microbial pillars. Each of these species offers distinct metabolic profiles and potential clinical applications that we validate through rigorous laboratory testing.
Beyond its traditional roles, this organism serves as a primary preclinical model for genetic engineering and the production of complex therapeutic proteins.
Distinguished by its rapid growth and "thermophilic" nature, it is an excellent candidate for preclinical studies on heat-stable oral delivery systems.
The industry workhorse for preclinical protein expression, capable of high-density fermentation and the secretion of correctly folded proteins.
Our Preclinical Research Services
Moving a fungus from a laboratory culture to a regulated drug candidate requires a multidisciplinary approach. Our CRO provides a comprehensive suite of services designed specifically for the unique challenges of fungal biology in the preclinical phase.
We provide deep phenotypic and genotypic profiling. This includes whole-genome sequencing (WGS) to ensure the absence of virulence factors. We also offer metabolic flux analysis to understand how the fungus will behave under the nutrient-limited conditions of the human gut during preclinical evaluation.
Advanced Genetic Engineering
Using gene editing and other synthetic biology tools, we can "program" your fungal strain to secrete specific therapeutic payloads. We specialize in optimizing signal peptides to ensure maximum secretion efficiency for preclinical proof-of-concept studies.
In Vitro and In Vivo Efficacy Testing
Our facilities are equipped with advanced organ-on-a-chip models that simulate the human intestinal interface. Following in vitro validation, we transition to specialized preclinical animal models (including germ-free and humanized microbiota mice) to evaluate the therapeutic impact on disease progression.
Safety and Toxicology Assessments
Safety is the cornerstone of preclinical development. We conduct rigorous compliant toxicology studies, including acute and chronic toxicity, translocation assays (to ensure the fungus does not enter the bloodstream), and "fungemia" risk assessments.
Premium Products for Preclinical Innovation
To support your internal R&D, we offer a catalog of high-quality products specifically tailored for preclinical fungal research:
Saccharomyces boulardii is sometimes used as a probiotic with the purpose of introducing beneficial microbes into the large and small intestines and conferring protection against pathogens.
This is a fluorescently labeled version of the probiotic yeast S. boulardii, widely used to treat diarrheal diseases. The addition of GFP allows for the real-time tracking of yeast survival and distribution throughout the digestive tract in animal models.
The probiotic yeast Saccharomyces cerevisiae is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals.
The probiotic yeast Saccharomyces cerevisiae is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals.
This product contains high-quality, intact genomic DNA isolated from Saccharomyces cerevisiae Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Saccharomyces cerevisiae var. ellipsoideus Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This is a mutant of the common baker's yeast that lacks a primary sensor for osmotic pressure. It is used to study how cells detect and respond to changes in their environment (like high salt or sugar concentrations).
This yeast strain is modified to disrupt the spliceosome, the machinery responsible for processing RNA. It is often a "conditional" mutant, as the loss of this gene is typically lethal under normal conditions.
These yeast strains have been modified to lack aquaporins, which are the "water channels" of the cell. These mutations affect how the yeast handles freezing and thawing.
The standard fluorescent reporter for baker's yeast. It is the primary model used in labs worldwide to study cell division, protein localization, and organelle health.
This is a specialized metabolic mutant that is unable to produce phosphatidylcholine (PC), the most common lipid in cell membranes, via the methylation pathway.
Saccharomyces cerevisiae DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Kluyveromyces lactis. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Kluyveromyces marxianus Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Kluyveromyces dobzhanskii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Kluyveromyces lactis DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Kluyveromyces marxianus DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Kluyveromyces dobzhanskii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Debaryomyces sp. Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Debaryomyces hansenii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Debaryomyces fabryi Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Debaryomyces Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Debaryomyces robertsiae Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Debaryomyces sp. DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Debaryomyces hansenii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Yarrowia lipolytica Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
This product contains high-quality, intact genomic DNA isolated from Yarrowia keelungensis Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Yarrowia lipolytica DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Yarrowia keelungensis DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Komagataella phaffii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Komagataella phaffii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Research Applications: Targeting Disease with Precision Fungi
The therapeutic application of these fungal strains is broad, touching upon oncology, immunology, and metabolic health. Our preclinical research teams are currently deep-diving into the following investigative directions:
The most established application involves the use of Saccharomyces boulardii and Saccharomyces cerevisiae in preclinical models of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). These fungi produce proteases that degrade toxins (such as those from C. difficile) and secrete anti-inflammatory molecules that strengthen the mucosal barrier. Our preclinical data show a significant reduction in pro-inflammatory cytokines like TNF-α and IL-6 following targeted fungal administration in rodent models.
Engineering yeasts like Yarrowia lipolytica allows for the production of specific fatty acids and carotenoids. Preclinical research is currently focused on using these engineered strains to address non-alcoholic fatty liver disease (NAFLD) and obesity by modulating the host's bile acid pool and improving insulin sensitivity in metabolic disease models.
3. Immuno-Oncology and Vaccine Delivery
Fungi are naturally "immunogenic," alerting the immune system to the presence of threats. We are exploring the preclinical use of fungal cell wall components, particularly β-glucans, as natural adjuvants. Furthermore, Komagataella phaffii is being utilized to express tumor-specific antigens, turning the fungal cell into a delivery vehicle for oral cancer vaccines being tested in preclinical oncology pipelines.
Non-conventional yeasts like Debaryomyces hansenii are showing promise in preclinical dermatological applications. By competing with pathogenic fungi and secreting antimicrobial peptides, these strains are being developed into topical LBPs for chronic wound healing and atopic dermatitis in skin-equivalent models.
Why Partner With Us? Our Preclinical Advantages
Choosing a CRO for fungal research requires a partner who understands that fungi are not just "large bacteria." Our advantages include:
Mycological Expertise
Our team consists of PhD-level mycologists who have spent decades studying fungal physiology and genetics in preclinical contexts.
Specialized Infrastructure
We maintain dedicated fungal suites to prevent cross-contamination and ensure the highest standards of biosafety and purity for preclinical data integrity.
Regulatory Insight
We stay at the forefront of evolving FDA and EMA guidelines for Live Biotherapeutic Products, ensuring your preclinical data package is built for regulatory success.
End-to-End Integration
From the initial "proof of concept" in a Petri dish to the final stability testing of a lyophilized product, we handle every step of the preclinical journey.
The potential of fungi in the realm of Live Biotherapeutics is vast and largely untapped. By harnessing the innate biological strengths of species like Saccharomyces and Yarrowia, and applying rigorous preclinical validation, we can unlock new treatments for some of the most challenging diseases of our time. The transition from "traditional probiotic" to "precision biotherapeutic" requires a foundation of high-quality data, innovative engineering, and uncompromising preclinical safety standards.
We invite you to explore the specific preclinical capabilities of our six focal strains by clicking the links above. Whether you are a biotech startup looking for your first proof-of-concept or an established pharmaceutical firm expanding your microbiome portfolio, our team is ready to accelerate your preclinical fungal research.
Why choose a fungus over a bacterium for a Live Biotherapeutic in preclinical studies?
Fungi are naturally resistant to many antibiotics, allowing for co-administration in preclinical models. They also have a much larger cell volume, enabling them to carry and secrete larger, more complex protein payloads.
How is safety evaluated during the preclinical phase?
This is a critical consideration. Our preclinical services include specific "translocation assays" and genetic attenuation strategies to ensure that the therapeutic strain remains localized and can be easily cleared by the host.
Can these fungi be engineered to target specific organs in animal models?
While they primarily reside in the gut or on the skin, engineered fungi can be designed to release systemic signals or metabolites that affect distant organs like the liver or brain, which we track using specialized preclinical imaging.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
